The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-24. Anything still debated is marked as such rather than presented as settled.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
== Structure and sequence == Xenin is a 25-amino acid polypeptide. The amino acid sequence of xenin is identical to the N-terminal end of cytoplasmic coatomer subunit alpha, from which xenin can be cleaved by aspartic proteases. Xenin is structurally related to the amphibian peptide xenopsin and to the neuropeptide neurotensin. Surpassed by insulin, xenin reflects the second highest degree of homology traced along the evolutionary tree among the regulatory peptides, indicating its prominent structural conservatism.
== Prognosis == Patient response to treatment will vary based on age, health, and the tolerance to medications and therapies. Metastasis occurs in about 39% of patients, most commonly to the lung. Features associated with poor prognosis include a large primary tumor (over 5 cm across), high grade disease, co-existent neurofibromatosis, and the presence of metastases. It is a rare tumor type, with a relatively poor prognosis in children. In addition, MPNSTs are extremely threatening in NF1. In a 10-year institutional review for the treatment of chemotherapy for MPNST in NF1, which followed the cases of 1 per 2,500 in 3,300 live births, chemotherapy did not seem to reduce mortality, and its effectiveness should be questioned. Although with recent approaches with the molecular biology of MPNSTs, new therapies and prognostic factors are being examined.
== Education == Daly attended Hunter College High School, a laboratory high school for girls run by Hunter College faculty, where she was also encouraged to pursue chemistry. She then enrolled in Queens College, a small, fairly new school in Flushing, New York. She lived at home to save money and graduated magna cum laude from Queens College with her bachelor's degree in chemistry in 1942. Upon graduation, she was named a Queens College Scholar, an honor that is awarded to the top 2.5% of the graduating class. Labor shortages and the need for scientists to support the war effort enabled Daly to garner fellowships to study at New York University and Columbia University for her master's and Ph.D. degrees, respectively. Daly worked as a laboratory assistant at Queens College while studying at New York University for her master's degree in chemistry, which she completed in 1943. She became a chemistry tutor at Queens College and enrolled in the doctoral program at Columbia University, where she was supervised by Mary Letitia Caldwell, for a Ph.D. thesis titled, "A Study of the Products Formed By the Action of Pancreatic Amylase on Corn Starch" and received her Ph.D. in chemistry in 1947.
Sources: en.wikipedia.org
In his 2011 paper Nature's Way of Making Audacious Space Projects Viable, he states that the Earth's non-renewable energy sources are nearly exhausted; natural gas will be depleted by 2020–2030, coal by 2035, uranium by 2056, while oil production peaked in 2006–2008. Nuclear energy cannot fully meet the world's energy needs (it represented only 6% in 2011). In addition, renewable energy cannot meet the growing demand for energy. Most of the minerals used by humans are in danger of becoming scarce; 11 minerals are already classified as having passed their peak production. For Metzger, humanity must therefore undertake a "100-year project" aimed at building a spacecraft ("100 Year Starship") capable of accessing the vast energy resources of the Solar System. For Metzger, it is even probable that if extraterrestrials coveted the energy resources of our Solar System, they would not look for them on Earth, but on the various asteroids and planetoids. Robotics is the only way to access so many dispersed resources, and humanity should embark on a second long-term project, which Metzger calls the "robotsphere", that would begin with the energetic exploitation of the Moon (estimated at 2.3×1012 J/year). This first step would make it possible to reach Type II in 53 years. Then the robotsphere (self-replicating and self-learning automated probes) would extend to the rest of the Solar System. Current advances in artificial intelligence suggest that the foundations of a robotsphere could be reached early in the next century, beginning in 2100.
=== Extra-articular symptoms === Autonomic dysfunction/dysautonomia: Symptoms may include orthostatic intolerance, dizziness, palpitations, Raynaud's phenomenon, and postural orthostatic tachycardia syndrome (POTS). Functional gastrointestinal disorders: Symptoms such as nausea, vomiting, diarrhea, constipation, bloating, early satiety, reflux, and irritable bowel syndrome. Pelvic and bladder dysfunction: Symptoms include pelvic pain, dyspareunia, bladder dysfunction, organ prolapse, and association with conditions like polycystic ovaries, fibroids, or endometriosis. Fatigue: Profound fatigue, often linked to sleep disturbances, non-restorative sleep, and nocturnal musculoskeletal pain, affecting concentration and quality of life. Mood disorders: Anxiety, depression, panic attacks, and emotional distress, often related to chronic pain and reduced physical function. Symptom expression varies widely, with different combinations and severities seen in individuals. Symptoms may fluctuate over time, often triggered by physical exertion, stress, illness, or injury.
Mesoamerican civilizations widely consumed cacao beverages, and in the 16th century, one of these beverages, chocolate, was introduced to Europe. Until the 19th century, chocolate was a drink consumed by societal elite. In the wake of technological advances chocolate became a mass-consumed solid food. Cocoa beans for most chocolate are grown in West African countries, particularly Ivory Coast and Ghana, which contribute about 60% of the world's cocoa supply.
=== Postwar and Cold War === In 1947, the TA was restructured and expanded through the reactivation of some of the 1st Line divisions that were initially disbanded after the war, keeping its former role of supplying complete divisions to the regular Army until 1967. For the first time, TA units were formed in Northern Ireland. The maneuver divisions established or re-established in 1947 were:
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.